) shares rose 1.8% in early New York trading on Wednesday after the company reported third-quarter results that topped analyst expectations.
In terms of specific product revenues, Biogen reported $1.16 billion in revenue for multiple sclerosis, in line with the estimate. Revenue for Spinraza reached $448.2 million, exceeding the estimate of $434.9 million.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: MarketWatch - 🏆 3. / 97 Lire la suite »